Interchange Capital Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$522K Buy
+3,297
New +$446K 0.1% 200
2025
Q3
Sell
-3,452
Closed -$286K 372
2025
Q2
$286K Buy
3,452
+780
+29% +$62.2K 0.07% 226
2025
Q1
$217K Buy
+2,672
New +$239K 0.06% 251
2024
Q4
Sell
-3,486
Closed -$344K 302
2024
Q3
$344K Sell
3,486
-5
-0.1% -$491 0.12% 183
2024
Q2
$324K Buy
+3,491
New +$313K 0.12% 183
2023
Q2
Sell
-1,272
Closed -$96.9K 232
2023
Q1
$96.9K Buy
+1,272
New +$106K 0.05% 211
2021
Q1
Sell
-325
Closed -$45K 1122
2020
Q4
$45K Buy
+325
New +$41.6K 0.02% 428

Other funds holding XBI

Interchange Capital Partners's XBI Position: Q2 2026 in Review

Interchange Capital Partners opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 3,297 shares worth $522K. The stake represents 0.1% of the portfolio and ranks #200 among its holdings. This is a return to the name: Interchange Capital Partners previously reported a position in XBI as recently as Q2 2025.

Interchange Capital Partners first reported a position in XBI in Q4 2020 and has held it in 7 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Interchange Capital Partners held 3,297 shares of State Street SPDR S&P Biotech ETF worth $522K as of Q2 2026.
  • State Street SPDR S&P Biotech ETF was a new Interchange Capital Partners position in Q2 2026.
  • State Street SPDR S&P Biotech ETF made up 0.1% of Interchange Capital Partners's portfolio in Q2 2026, its #200 holding.
  • Interchange Capital Partners first reported a position in State Street SPDR S&P Biotech ETF in Q4 2020 and has held it in 7 quarters since.
  • 933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Interchange Capital Partners's 13F filing for Q2 2026, filed 20 Jul 2026.